Open access
Clinical trial: The Effect on Intragastric pH and Pharmacokinetics of the PCAB Linaprazan Glurate in Healthy Subjects After Repeat‐Dose Administration for up to 14 Days
Kajsa Larsson
Kjell Andersson
Gunilla Huledal
J. Junnila
Kristofer Katkits Nilsson
Elham Yektaei
M. Fležar
Peter Unge
Oct 2026 · Alimentary Pharmacology and Therapeutics · Vol 64, pp. 1390 - 1401 · 0 citations
· 17 references
Medicine
Abstract
Linaprazan glurate (LG), a potassium‐competitive acid blocker (PCAB), has shown up to 100% and 93% 4‐week healing rates in a Phase 2 study in patients with LA grade A/B and C/D erosive oesophagitis, respectively.